AEON Biopharma

Revenue visibility is nil pending FDA outcomes and any required clinical equivalence. Management targets completion of most analytical work in 2026 and a Type 2b meeting in 2H26, but timelines to a 351(k) BLA and potential approval depend on the scope of pharmacodynamic/clinical requirements the FDA sets.

Clinical history adds uncertainty: episodic‑migraine Phase 2 was negative and the chronic‑migraine interim analysis did not meet its primary endpoint in 2024, supporting the pivot but underscoring development risk.

Geographic and supply concentration risks exist given single‑supplier dependence on Daewoong, though facilities have passed U.S./EU inspections for toxin manufacturing. Overall predictability remains low until FDA minutes specify the remaining package and AEON demonstrates execution.